- Immunomedics (IMMU) rises 12% in premarket action.
- The company announced a new patent in its antibody-drug conjugates intellectual property family.
- Specifically, the new patent "relates to [IMMU's] proprietary linker technology for conjugating SN-38 to the company's humanized antibodies for targeted delivery of the potent drug to the tumor." (PR)
Immunomedics announces new patent, shares rise
Dec 31 2013, 09:05 ET